Alvogen, Inc. (United States) holds 1 active US FDA Type II Drug Master File and has DMF or CEP filings on record for 1 active ingredient. 25 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Alvogen, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/alvogen-inc

Overview

Alvogen, Inc. is a global pharmaceutical company that specializes in the development, manufacturing, and marketing of generic, brand, and over-the-counter products. The company has a broad global footprint and focuses on delivering high-quality medications with a diverse portfolio across many therapeutic areas.

Core services & business areas

Pharmaceutical ManufacturingMarketingRegulatory AffairsProduct DevelopmentDistribution

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Alvogen, Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Alvogen, Inc. holds 1 active (1 total) FDA Type II Drug Master File. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • PYRIMETHAMINEActive2019-05-28

FDA compliance signals

25 FDA enforcement records linked to this company.

  • recall — Class II2026-01-21

    Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.

  • recall — Class I2025-02-26

    Defective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.

  • recall — Class II2023-03-08

    Sub-Potent Drug: Out of specification for assay at the 24 month interval.

  • recall — Class II2021-07-14

    Subpotent drug: Out of specification for assay of naloxone and buprenorphine (low)

  • 4832021-06-10

    Failure to comply with REMS Implementation System

  • 4832020-09-11

    Interval

  • 4832020-09-11

    Late submission of 15-day report

  • 4832020-09-11

    Failure to develop written procedures

  • recall — Class II2019-08-21

    Failed dissolution specifications

  • recall — Class II2019-08-21

    Failed dissolution specifications

  • recall — Class I2019-05-15

    Product Mix-Up: Customer complaint that their carton labeled as Fentanyl Transdermal Systems, 12 mcg/h contained five patches labeled and containing 50 mcg/h.

  • recall — Class II2017-07-12

    Lack of Assurance of Sterility

  • recall — Class II2017-07-12

    Lack of Assurance of Sterility

  • recall — Class II2017-07-12

    Lack of Assurance of Sterility

  • recall — Class III2017-04-12

    Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

  • recall — Class III2017-04-12

    Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

  • recall — Class III2017-04-12

    Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

  • recall — Class III2017-04-12

    Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

  • recall — Class III2017-04-12

    Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

  • recall — Class III2017-04-12

    Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

  • recall — Class III2017-04-12

    Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

  • recall — Class III2017-04-12

    Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

  • recall — Class III2017-04-12

    Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

  • recall — Class II2015-05-20

    Failed Dissolution Specification; 6 month time point

  • recall — Class II2014-10-01

    Failed Content Uniformity Specifications - The lot failed to meet the acceptance criteria for Uniformity of Dosage Units at the time of release for the oxycodone component.

For suppliers

Is this Alvogen, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.